Section Arrow
SPRY.NASDAQ
- ARS Pharmaceuticals
Quotes are at least 15-min delayed:2025/09/01 10:29 EDT
Regular Hours
Last
 11.62
-1.24 (-9.64%)
Day High 
12.7 
Prev. Close
12.86 
1-M High
18.5 
Volume 
7.18M 
Bid
11.6
Ask
11.9
Day Low
10.98 
Open
12.7 
1-M Low
12.84 
Market Cap 
1.27B 
Currency USD 
P/E 170 
%Yield -- 
10-SMA 13.9 
20-SMA 15.39 
50-SMA 16.63 
52-W High 18.9 
52-W Low 10 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.48/-0.17
Enterprise Value
1.27B
Balance Sheet
Book Value Per Share
1.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
89.15M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/09/01 10:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.